March 16, 2026The Oncologist0 citationsOpen Access

Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer

Q: What does this research mean for the field?

Everolimus-related interstitial lung disease (e-rILD) does not influence the choice of subsequent treatment in patients with metastatic breast cancer. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

HKHikari KiyoharaTokai University CKChihiro KondohSaitama Cancer Center AHAkira HirotaNational Cancer Center Hospital East

Key Points

To assess the influence of everolimus-related interstitial lung disease on subsequent treatment decisions in metastatic breast cancer.
Analysis of patients with metastatic breast cancer receiving everolimus
Evaluation of treatment choices following interstitial lung disease diagnosis
Assessment of drug-related ILD during subsequent treatments
Everolimus-related interstitial lung disease did not impact subsequent treatment choices.
No significant increase in drug-related ILD development during later treatments was observed.

Abstract

e-rILD may not influence the choice of following treatment or the development of drug-related ILD during subsequent treatments.

问 AI

Bookmark

View Full Paper